secwatch.observer — SEC 8-K summary
======================================

Issuer:     GridAI Technologies Corp. (GRDX)
CIK:        0001604191
Form:       8-K
Filed at:   2024-03-14T23:59:59+00:00
Accession:  0001104659-24-034161
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.85
Item codes: 1.01, 5.03, 2.01, 2.03, 3.02, 3.03, 5.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

First Wave BioPharma completes acquisition of ImmunogenX in stock deal
----------------------------------------------------------------------

- Issued 36,830 common shares and 11,777 Series G shares (convertible into 11.8M common shares) to ImmunogenX holders.
- Assumed ImmunogenX stock options for 200,652 shares at $0.81 and warrants for 127,682 shares at $3.02-$3.92.
- Post-merger common shares outstanding: 1,974,744; Series G conversion requires stockholder approval.
- Appointed Jack Syage (President/COO) and Chaitan Khosla as directors; board expanded to 7.
- Amended credit facility with Mattress Liquidators: $8.2M commitment, maturity Sept 2025, interest rate prime+6%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1604191/000110465924034161/0001104659-24-034161-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1604191/000110465924034161/tm248020d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-034161

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer